{"id":"dfa67013e9c2","type":"article","url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","title":"CCTA-afgeleide FFR: prognostische waarde — meta-analyse","title_en":"Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["fractional-flow-reserve"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319773","source_url":"https://doi.org/10.1136/heartjnl-2021-319773","authors":["Bjarne L Nørgaard","Sara Gaur","Timothy A Fairbairn","Pam S Douglas","Jesper M Jensen","Manesh R Patel","Abdul R Ihdayhid","Brian S H Ko","Stephanie L Sellers","Jonathan Weir-McCall","Hitoshi Matsuo","Niels Peter R Sand","Kristian A Øvrehus","Campbell Rogers","Sarah Mullen","Koen Nieman","Erik Parner","Jonathon Leipsic","Jawdat Abdulla"],"significance":6,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-ct-angiografie/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"This meta-analysis evaluated the prognostic value of CT-derived fractional flow reserve (FFR-CT), showing that non-invasive physiological assessment of coronary stenoses predicts future cardiovascular events beyond anatomical assessment alone.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Systematische review en meta-analyse naar de prognostische waarde van CT-afgeleide fractional flow reserve.","abstract_original":"OBJECTIVES: To obtain more powerful assessment of the prognostic value of fractional flow reserveCT testing we performed a systematic literature review and collaborative meta-analysis of studies that assessed clinical outcomes of CT-derived calculation of FFR (FFRCT) (HeartFlow) analysis in patients with stable coronary artery disease (CAD). METHODS: We searched PubMed and Web of Science electronic databases for published studies that evaluated clinical outcomes following fractional flow reserveCT testing between 1 January 2010 and 31 December 2020. The primary endpoint was defined as 'all-cause mortality (ACM) or myocardial infarction (MI)' at 12-month follow-up. Exploratory analyses were performed using major adverse cardiovascular events (MACEs, ACM+MI+unplanned revascularisation), ACM, MI, spontaneous MI or unplanned (>3 months) revascularisation as the endpoint. RESULTS: Five studies were identified including a total of 5460 patients eligible for meta-analyses. The primary endpoint occurred in 60 (1.1%) patients, 0.6% (13/2126) with FFRCT>0.80% and 1.4% (47/3334) with FFRCT ≤0.80 (relative risk (RR) 2.31 (95% CI 1.29 to 4.13), p=0.005). Likewise, MACE, MI, spontaneous MI or unplanned revascularisation occurred more frequently in patients with FFRCT ≤0.80 versus patients with FFRCT >0.80. Each 0.10-unit FFRCT reduction was associated with a greater risk of the primary endpoint (RR 1.67 (95% CI 1.47 to 1.87), p<0.001). CONCLUSIONS: The 12-month outcomes in patients with stable CAD show low rates of events in those with a negative FFRCT result, and lower risk of an unfavourable outcome in patients with a negative test result compared with patients with a positive test result. Moreover, the FFRCT numerical value was inversely associated with outcomes."}